@vasculitides
banner
vasculitides.bsky.social
@vasculitides
@vasculitides.bsky.social
Living with EGPA/Churg-Strauss Syndrome • NIH-funded researcher • vasculitis patient advocate
www.vasculitides.com
Pinned
Access our new review on diagnosis, classification, and prognosis of ANCA-associated vasculitis in Nat Rev Rheum for free at rdcu.be/eL3wJ
Mosunetuzumab, a CD20xCD3 bispecific T-cell engager, in granulomatosis with polyangiitis
Mosunetuzumab, a CD20xCD3 bispecific T-cell engager, in granulomatosis with polyangiitis - PubMed
Mosunetuzumab, a CD20xCD3 bispecific T-cell engager, in granulomatosis with polyangiitis
pubmed.ncbi.nlm.nih.gov
November 28, 2025 at 11:16 PM
Can HALP Score Predict the Prognosis of Patients With Giant Cell Arteritis and Polymyalgia Rheumatica?
Can HALP Score Predict the Prognosis of Patients With Giant Cell Arteritis and Polymyalgia Rheumatica? - PubMed
These findings suggest that lower HALP scores may be associated with both prolonged GC dependency and increased risk of death.
pubmed.ncbi.nlm.nih.gov
November 28, 2025 at 11:15 PM
Treatment strategies and outcomes in adult relapsing or refractory cutaneous IgA Vasculitis: A multicenter retrospective cohort study
Treatment strategies and outcomes in adult relapsing or refractory cutaneous IgA Vasculitis: A multicenter retrospective cohort study - PubMed
In adult relapsing or refractory cutaneous IgA vasculitis, dapsone, GCs and cDMARDs provided the highest rates of cutaneous response. Considering the risk-benefit ratio and potential adverse events, dapsone appears to be an interesting option in adult relapsing or refractory cutaneous IgA vasculitis …
pubmed.ncbi.nlm.nih.gov
November 28, 2025 at 11:15 PM
Diagnostic and prognostic utility of complete blood count-derived ratios in giant cell arteritis: a retrospective fast-track clinic cohort stud
Diagnostic and prognostic utility of complete blood count-derived ratios in giant cell arteritis: a retrospective fast-track clinic cohort study - PubMed
Early diagnosis and treatment of giant cell arteritis (GCA) can prevent complications like vision loss. Traditional inflammatory markers C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) lack specificity. Complete blood count (CBC) components (neutrophil-to-lymphocyte ratio (NLR), pl …
pubmed.ncbi.nlm.nih.gov
November 28, 2025 at 11:13 PM
Coronary vasospasms and other cardiac manifestations in Eosinophilic Granulomatosis with Polyangiitis: Clinical impact and frequency in a monocentre study of 103 patients
Coronary vasospasms and other cardiac manifestations in Eosinophilic Granulomatosis with Polyangiitis: Clinical impact and frequency in a monocentre study of 103 patients - PubMed
Cardiac involvement is a common initial manifestation of EGPA and is associated with elevated systemic disease activity. In addition to pericarditis and myocarditis, coronary vasospasms were identified as a rare and severe manifestation of EGPA that may mimic myocardial infarction. Consequently, at …
pubmed.ncbi.nlm.nih.gov
November 28, 2025 at 11:09 PM
Postpartum Hybrid Aortic Aneurysm Repair in the Setting of Takayasu Arteritis
Postpartum Hybrid Aortic Aneurysm Repair in the Setting of Takayasu Arteritis - PubMed
We present a rare case of postpartum aortic aneurysm repair in a patient with Takayasu arteritis.
pubmed.ncbi.nlm.nih.gov
November 28, 2025 at 11:08 PM
Repeated short corticotropin testing in patients with polymyalgia rheumatica
Repeated short corticotropin testing in patients with polymyalgia rheumatica - PubMed
Clinicaltrials.gov; NCT04519580.
pubmed.ncbi.nlm.nih.gov
November 28, 2025 at 11:07 PM
Paeoniflorin Alleviates Coronary Artery Lesions in Kawasaki Disease by Activating NRF2 Pathway and Inhibiting CYP2E1 Expression
Paeoniflorin Alleviates Coronary Artery Lesions in Kawasaki Disease by Activating NRF2 Pathway and Inhibiting CYP2E1 Expression - PubMed
Collectively, our findings demonstrated that PF alleviated CAL in KD by activating NRF2 pathway and inhibiting CYP2E1 expression. These results may provide a theoretical basis for the potential use of PF as a therapeutic agent for KD associated with CAL.
pubmed.ncbi.nlm.nih.gov
November 28, 2025 at 11:07 PM
Asymmetric dimethylarginine as a predictive marker for resistance to high-dose intravenous immunoglobulin in Kawasaki disease
Asymmetric dimethylarginine as a predictive marker for resistance to high-dose intravenous immunoglobulin in Kawasaki disease - PubMed
• Asymmetric dimethylarginine levels may be useful for the prediction of resistance to initial and additional IVIG treatment.
pubmed.ncbi.nlm.nih.gov
November 28, 2025 at 11:06 PM
Epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis in Lithuania, 2012-2021: a retrospective cohort study
Epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis in Lithuania, 2012-2021: a retrospective cohort study - PubMed
AAV is associated with increased mortality. During the study period, the incidence of AAV was found to be stable, and the prevalence has increased.
pubmed.ncbi.nlm.nih.gov
November 28, 2025 at 11:06 PM
Buerger's Disease: Successful Management of Acute Cutaneous Features and Achieving Disease Remission With Pentoxifylline
Buerger's Disease: Successful Management of Acute Cutaneous Features and Achieving Disease Remission With Pentoxifylline - PubMed
Buerger's disease or thromboangiitis obliterans is a nonatherosclerotic inflammatory disease that affects the small and medium-sized arteries in the extremities. We describe a 46-year-old man with Buerger's disease, who achieved regression of acute ulceration of his lower limbs and remission of his …
pubmed.ncbi.nlm.nih.gov
November 28, 2025 at 11:05 PM
Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab
ClinicalTrials.gov
clinicaltrials.gov
November 28, 2025 at 11:04 PM
Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides
ClinicalTrials.gov
clinicaltrials.gov
November 28, 2025 at 11:03 PM
Efficacy Study of Two Treatments in the Remission of Vasculitis
ClinicalTrials.gov
clinicaltrials.gov
November 28, 2025 at 11:03 PM